Please assess the completion status of the following clinical trial:

Trial Title: Demonstrate Noninferiority in Efficacy and to Assess Safety of CT-P13 in Patients With Active Crohn's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female patients with active Crohn's disease and a Crohn's disease activity index score between 220 and 450 points~Exclusion Criteria:~* Patient who has previously received a biological agent for the treatment of Crohn's disease and/or a Tumor necrosis factor (TNF)-alpha inhibitor for the treatment of other disease.~* Patient who has allergies to any of the excipients of infliximab, any other murine and/or human proteins, or patient with a hypersensitivity to immunoglobulin product.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- CT-P13 - CT-P13 (Type: EXPERIMENTAL): CT-P13 followed by CT-P13 from Week 30
- CT-P13 - Remicade (Type: ACTIVE_COMPARATOR): CT-P13 followed by Remicade from Week 30
- Remicade - Remicade (Type: ACTIVE_COMPARATOR): Remicade followed by Remicade from Week 30
- Remicade - CT-P13 (Type: EXPERIMENTAL): Remicade followed by CT-P13 from Week 30

Based on this trial design, predict the completion outcome and termination type (if applicable).